Remedy Meds: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://remedymeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   “The following claims concerning compounded semaglutide and tirzepatide products appear on your website: "Semaglutide (Compounded) Same active ingredient as Ozempic and Wegovy" "Tirzepatide (Compounded) Same active ingredient as Mounjaro and Zepbound"”

2. 2

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

remedymeds.com returned a live storefront when we checked in August 2026, still operating under the Remedy Meds name.

The claim FDA flagged here is a straightforward same-active-ingredient comparison run as a product label on Remedy Meds' own site. It doesn't say the compounded product doesn't work — it says labeling it next to "Ozempic and Wegovy" and "Mounjaro and Zepbound" implied an FDA evaluation that hasn't happened. Weigh any brand-name comparison on this provider's pricing pages accordingly.

Doseworth’s review of Remedy Meds has the pricing, the states served, and what’s included.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Remedy Meds failed to respond.